Published 1 day ago • loading... • Updated 16 hours ago

CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

CARsgen Therapeutics Holdings Limited's satricabtagene autoleucel, known as satri-cel, has been granted Breakthrough Therapy Designation by the National Medical Products Administration for treating Claudin18.2-positive advanced gastric cancer.
The therapy is intended for patients who have failed at least two prior lines of treatment.
CARsgen plans to submit a New Drug Application for satri-cel to the NMPA in the first half of 2025.

Insights by Ground AI

Does this summary seem wrong?

39 Articles

All

Left

Center

Right

Science News

A child who got CAR-T cancer therapy is still disease-free 18 years later

The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

17 hours ago·United States

Read Full Article

Charleston Gazette-Mail

+36 Reposted by 36 other sources

CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China's…

1 day ago·Charleston, United States

Read Full Article

cancernetwork.com

DLBCL in Focus: Transforming Outcomes With CAR T Therapy

Panelists discuss how the diffuse large B-cell lymphoma (DLBCL) treatment landscape has seen significant evolution with the integration of targeted therapies and chimeric antigen receptor T-cell treatments, supplementing traditional R-CHOP. However, early relapsed/refractory cases remain challenging due to complex tumor biology and resistance mechanisms. This underscores the need for better up-front risk stratification tools and biomarker-driven…

16 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year